Treatment News : Boosting Agent Cobicistat Comparable to Norvir in Phase III Study

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » December 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

December 5, 2011

Boosting Agent Cobicistat Comparable to Norvir in Phase III Study

Compared with Norvir (ritonavir), people living with HIV using Gilead Sciences’ novel boosting agent cobicistat were just as likely to see their viral loads drop to undetectable levels and no more likely to discontinue therapy due to side effects, according to preliminary results from a Phase III study comparing both drugs in combination with Reyataz (atazanavir) and Truvada (tenofovir plus emtricitabine). The study’s findings, highlighted in a December 5 statement from cobicistat’s developer Gilead Sciences, will be presented in full at a scientific conference sometime in 2012, with an approval application likely to be submitted to the FDA sometime this spring.

Cobicistat, formerly known as GS-9350, is an experimental pharmacokinetic enhancer—a drug used to boost other medications in the blood to make them more effective. It is being developed as an alternative to Norvir, a protease inhibitor (PI) once used to treat HIV but now prescribed at low doses to boost the blood levels of other PIs, notably Reyataz, Lexiva (fosamprenavir), Prezista (darunavir), Aptivus (tipranavir) and Kaletra (lopinavir plus ritonavir).

Cobicistat’s potential as a Norvir alternative is important. For starters, while it has a pronounced effect on the enzyme system (CYP3A) responsible for breaking down several HIV drugs, it doesn’t affect other enzyme systems used by many other medications—a common problem with Norvir that contributes to numerous potentially harmful drug interactions. The drug also doesn’t impair fat cell functions like Norvir does, at least not in test tube studies, meaning that cobicistat may be less likely to count fat accumulation and insulin sensitivity problems as side effects.

Gilead has been committed to testing cobicistat as a stand-alone drug in combination with other companies’ drugs that generally require boosting. Gilead is also exploring cobicistat in combination with its experimental integrase inhibitor elvitegravir and Truvada as a once-daily fixed-dose combination tablet.   

Study 114, a Phase III clinical trial, was conducted by Gilead to explore the effectiveness and safety of cobicistat-boosted Reyataz versus Norvir-boosted Reyataz over a 96-week period at more than 200 study sites internationally. The researchers allotted nearly 700 HIV-positive individuals starting antiretroviral therapy for the first time to receive 150 milligrams (mg) cobicistat of 100 mg Norvir, both in combination with Reyataz and Truvada (tenofovir plus emtricitabine). 

Similar rates of virologic suppression—defined as a viral load below 50 copies—were maintained through the follow-up period. After 48 weeks of treatment, 85 percent in the cobicistat group and 87 percent in the Norvir group had viral loads below 50 copies/mL. Given the similar response rates in the two groups, cobicistat was considered to be “non-inferior” to Norvir.

As for adverse health outcomes, the Gilead statement notes similar side effect-related discontinuation rates in both groups. Approximately 7.3 percent of those receiving cobicistat-boosted Reyataz plus Truvada discontinued therapy because of adverse events, compared with 7.2 percent of patients receiving Norvir-boosted Reyataz plus Truvada.

One particular adverse event was noted in the press release. Small increases in serum creatinine—a lab test used to measure kidney function—with resulting decreases in estimated creatine clearance were observed in the study. After 48 weeks of treatment, the average increase in serum creatinine was 0.14 milligrams per deciliter (mg/dL) among those receiving cobicistat, compared with a 0.09 mg/dL serum creatinine increase among those in the Norvir group.

“The increase in serum creatinine with cobicistat occurs with days of drug initiation and is reversible with values returning to [pre-treatment levels] with days after [discontinuing] cobicistat,” Gilead clarifies, adding that cobicistat didn’t have an effect on other measures of renal function,  including actual glomerular filtrates rates (GFR).

“These results demonstrate that cobicistat may provide patients taking protease-based regimens with a much-needed alternative boosting agent,” Norbert Bischofberger, PhD, Gilead’s chief scientific officer, is quoted as saying in the statement. “We are now working toward a second quarter 2012 U.S. regulatory filing for cobicistat.”

Search: cobicistat, ritonavir, Norvir, Gilead, quad, non-inferior, comparable


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    TanyaB
    Delray Beach
    Florida


    max38man
    Chicago
    Illinois


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.